Comparative efficacy of different acute reperfusion therapies for acute ischemic stroke: A comprehensive benefit-risk analysis of clinical trials

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:2998841 21 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
Comparative efficacy of different acute reperfusion therapies for acute ischemic stroke: A comprehensive benefit-risk analysis of clinical trials
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: Numerous acute reperfusion therapies (RPT) are currently investigated as potential new therapeutic targets in acute ischemic stroke (AIS). We conducted a comprehensive benefit-risk analysis of available clinical studies assessing different acute RPT, and investigated the utility of each intervention in comparison to standard intravenous thrombolysis (IVT) and in relation to the onset-to-treatment time (OTT). Methods: A comprehensive literature search was conducted to identify all available published, peer-reviewed clinical studies that evaluated the efficacy of different RPT in AIS. Benefit-to-risk ratio (BRR), adjusted for baseline stroke severity, was estimated as the percentage of patients achieving favorable functional outcome (BRR1, mRS score: 0-1) or functional independence (BRR2, mRS score: 0-2) at 3 months divided by the percentage of patients who died during the same period. Results: A total of 18 randomized (n = 13) and nonrandomized (n = 5) clinical studies fulfilled our inclusion criteria. IV therapy with tenecteplase (TNK) was found to have the highest BRRs (BRR1 = 5.76 and BRR2 = 6.82 for low-dose TNK; BRR1 = 5.80 and BRR2 = 6.87 for high-dose TNK), followed by sonothrombolysis (BRR1 = 2.75 and BRR2 = 3.38), while endovascular thrombectomy with MERCI retriever was found to have the lowest BRRs (BRR1 range, 0.31-0.65; BRR2 range, 0.52-1.18). A second degree negative polynomial correlation was detected between favorable functional outcome and OTT (R2 value: 0.6419; P < 0.00001) indicating the time dependency of clinical efficacy of all reperfusion therapies. Conclusion: Intravenous thrombolysis (IVT) with TNK and sonothrombolysis have the higher BRR among investigational reperfusion therapies. The combination of sonothrombolysis with IV administration of TNK appears a potentially promising therapeutic option deserving further investigation. © 2014 The Authors. Brain and Behavior published by Wiley Periodicals, Inc.
Έτος δημοσίευσης:
2014
Συγγραφείς:
Tsivgoulis, G.
Alleman, J.
Katsanos, A.H.
Barreto, A.D.
Kohrmann, M.
Schellinger, P.D.
Molina, C.A.
Alexandrov, A.V.
Περιοδικό:
Brain and Behavior
Εκδότης:
John Wiley and Sons Ltd
Τόμος:
4
Αριθμός / τεύχος:
6
Σελίδες:
789-797
Λέξεις-κλειδιά:
alteplase; tenecteplase; fibrinolytic agent; tenecteplase; tissue plasminogen activator, bibliographic database; blood clot lysis; brain hemorrhage; brain ischemia; cerebrovascular accident; comparative effectiveness; functional assessment; human; intracranial retriever device; mechanical thrombectomy; meta analysis; mortality; multicenter study (topic); National Institutes of Health Stroke Scale; percutaneous thrombectomy; priority journal; randomized controlled trial (topic); Rankin scale; reperfusion; Review; risk benefit analysis; sonothrombolysis; time to treatment; treatment outcome; brain ischemia; clinical trial (topic); procedures; reperfusion; risk assessment; Stroke; ultrasound therapy, Brain Ischemia; Clinical Trials as Topic; Fibrinolytic Agents; Humans; Reperfusion; Risk Assessment; Stroke; Tissue Plasminogen Activator; Ultrasonic Therapy
Επίσημο URL (Εκδότης):
DOI:
10.1002/brb3.279
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.